Sign in

You're signed outSign in or to get full access.

Howard T. Slayen

Director at AEHR TEST SYSTEMSAEHR TEST SYSTEMS
Board

About Howard T. Slayen

Howard T. Slayen, age 78, has served as an independent director of Aehr Test Systems since 2008. He is a former Corporate Finance Partner at PricewaterhouseCoopers (1971–1999) and former EVP & CFO of Quaartz Inc. (1999–2001), and has provided independent financial consulting since 2001; he holds a B.A. from Claremont McKenna College and a J.D. from UC Berkeley School of Law . The Board has determined he is independent and designated him an “audit committee financial expert” under SEC rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
PricewaterhouseCoopers LLP (and predecessor)Corporate Finance Partner1971–1999Corporate finance expertise; advised high‑tech companies
Quaartz Inc.EVP & CFOOct 1999–May 2001Senior financial leadership in web‑hosted communications
Independent ConsultingFinancial ConsultantSince Jun 2001Advisory to various organizations/clients

External Roles

OrganizationRoleTenureNotes
Several non‑profit organizationsDirector/Committee memberNot disclosedCurrent service noted (names not specified)
Public company boards (current)No current public directorships disclosed in proxy biography
Public company boards (prior)Audit Committee Chair (two public technology companies)Prior serviceFormer chair roles noted (names not specified)

Board Governance

ItemDetail
Board/Committee attendance (FY2025)100% attendance at Board and committee meetings for all directors
CommitteesAudit (Chair); Compensation (Member)
Audit Committee meetings (FY2025)4 meetings; Slayen serves as Chair and is the Board’s SEC-defined “audit committee financial expert”
Compensation Committee meetings (FY2025)2 meetings; Slayen is a member
IndependenceIndependent under Nasdaq and SEC rules
Board structureSeparate Chair (independent) and CEO; no lead independent director given independent Chair

Fixed Compensation

Fiscal YearCash RetainerCommittee Chair FeesMeeting FeesTotal Cash
2025$72,500 (Audit Chair) $0 (not disclosed) $72,500

Notes:

  • Standard director compensation policy in effect for FY2025: Audit and Compensation Committee Chairs receive $72,500 cash and $140,000 in RSUs; other non‑chair directors receive $65,000 cash and $140,000 RSUs; Chairman receives $85,000 cash and $160,000 RSUs; RSUs vest over two years (1/8 quarterly) .

Performance Compensation

Grant/PeriodInstrumentGrant DateQuantity/ValueVesting/Performance Terms
Annual director equity (FY2025)RSUsOct 2024$140,000 fair value for each outside director; Slayen awarded RSUs consistent with policy Vests 1/8 each quarterly anniversary over two years, subject to continued service
Annual RSUs (share count disclosure)RSUsOct 20249,265 RSUs to each outside director (including Slayen) Time-based as above

Additional notes:

  • Director equity awards are time‑based; no director‑level performance metrics or PSUs are disclosed for non‑employee directors .

Other Directorships & Interlocks

CompanyRoleCommittee RolesInterlock/Overlap
None disclosed (current public companies)No current public company interlocks disclosed

Expertise & Qualifications

  • Audit committee financial expert (SEC definition) and Audit Committee Chair .
  • Former corporate finance partner (PwC) and public‑company CFO, with deep experience in accounting, financial reporting, financing, investing, internal controls, and compliance; prior service as audit committee chair at two other public technology companies .
  • Legal training (J.D.), enhancing oversight of compliance and governance matters .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotable Details
Howard T. Slayen218,397 <1% Includes 2,872 RSUs vesting within 60 days of Aug 28, 2025
RSUs held at FY2025 end6,906 RSUs (Slayen) FY2025 year‑end unvested RSUs per director holdings table
Options outstanding (FY2025)0 (no options reported for Slayen) Options outstanding disclosed for other directors; none listed for Slayen

Ownership alignment and policies:

  • Director stock ownership guideline: at least one year of cash compensation; all directors are required to maintain ownership at that level (compliance status not individually disclosed) .
  • Company Insider Trading Policy prohibits hedging, short sales, options/derivatives, and pledging or purchasing on margin; this mitigates alignment risks from hedging/pledging .

Governance Assessment

  • Strengths and signals supporting investor confidence:

    • Independent director, Audit Chair, and SEC-defined audit committee financial expert; strong accounting and internal control pedigree (PwC partner; public‑company CFO) .
    • High engagement: 100% Board and committee attendance in FY2025 .
    • Pay structure aligned with best practices for small-cap tech: modest cash retainer and majority of director comp in time‑vested equity; ownership guideline in place .
    • Robust controls environment indicators: clawback policy covering equity awards under the plan; explicit prohibition on repricing options/SARs without shareholder approval; insider trading policy bans hedging/pledging .
    • No related‑party transactions disclosed in the proxy beyond policy description, reducing conflict risk .
  • Watch items / potential risks:

    • Concentration of responsibilities: serves on both Audit (Chair) and Compensation Committees; while common at smaller issuers, workload/independence optics warrant monitoring as complexity grows .
    • Change‑in‑control acceleration: non‑employee director awards fully vest on a change in control—standard but can be scrutinized by governance-focused investors .
  • Shareholder sentiment context:

    • Say‑on‑pay in Oct 2025: 11,178,940 For; 1,610,314 Against; 98,156 Abstain; broker non‑votes 7,269,294 (board comp oversight signal consistent with broad support) .

Overall, Slayen’s deep finance background and designation as audit committee financial expert, combined with perfect attendance and an equity‑heavy director pay mix under restrictive hedging/pledging policies, are positives for board effectiveness and investor alignment. No specific conflicts or related‑party exposures are disclosed in the proxy .